stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 31 | 31 | 72 | +51.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EBT | — | — | — | — | (17) | (43) | (68) | (100) | (134) | (168) | 1,165 | +57.8% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | (17) | (43) | (68) | (100) | (134) | (168) | 1,010 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (23.17) | (1.14) | (1.27) | (1.57) | (1.45) | (1.63) | 9.25 | (41.2%) | ||||||
| Cash flow | — | — | — | — | (19.80) | (0.89) | (0.98) | (1.44) | (1.18) | (1.40) | (1.85) | (41.2%) | ||||||
| Capex | — | — | — | — | (0.27) | (0.02) | (0.10) | (0.09) | (0.01) | 0.00 | 0.00 | (60.9%) | ||||||
| Free cash flow | — | — | — | — | (20.08) | (0.91) | (1.09) | (1.53) | (1.19) | (1.40) | (1.86) | (41.3%) | ||||||
| Book value | — | — | — | — | 171.58 | 7.31 | 6.47 | 5.00 | 4.97 | 5.07 | 15.00 | (50.5%) | ||||||
| Shares, m | — | — | — | — | 1 | 38 | 54 | 64 | 92 | 103 | 107 | +168.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (15) | (34) | (53) | (92) | (109) | (144) | (202) | +57.9% | |||||
| Capex | — | — | — | — | 0 | (1) | (6) | (6) | (1) | 0 | 0 | +4.7% | ||||||
| Free cash flow | — | — | — | — | (15) | (34) | (58) | (98) | (110) | (144) | (202) | +57.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 125 | 273 | 340 | 310 | 452 | 516 | 1,628 | +32.7% | |||||
| Net debt | — | — | — | — | (129) | (281) | (352) | (318) | (470) | (530) | (1,744) | +32.6% | ||||||
| Shareholders’ equity | — | — | — | — | 127 | 274 | 347 | 319 | 459 | 522 | 1,633 | +32.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (26.11) | (20.56) | (20.74) | (28.33) | (32.37) | (32.29) | 85.43 | (6.2) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (16,355.41) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (14.21) | (35.53) | (21.78) | (30.10) | (34.40) | (34.19) | 92.15 | (20.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 19 | 31 | 59 | 88 | 110 | 146 | — | +50.4% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 6 Nov 2026
Edgewise Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR | $4.4B | — (loss-making) | — (loss-making) | +51.90% (above 0%: growing) | n/m | −26.79% (below 0%: shrinking) | 64.54% | 14.37% | Compare |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | — (loss-making) | — | — | n/m | −30.24% (below 0%: shrinking) | 0.00% | 0.00% | |
| DFTX Definium Therapeutics, Inc. | $4.1B | — (loss-making) | — | — | n/m | −78.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RLAY Relay Therapeutics, Inc. | $3.7B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | (25,949.71%) | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | — (loss-making) | — (loss-making) | +100.70% (above 0%: growing) | n/m | −48.57% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ABCL AbCellera Biologics Inc. | $3.6B | — (loss-making) | — (loss-making) | −76.29% (below 0%: shrinking) | n/m | +151.98% (above 0%: growing) | 100.00% | (1,550.05%) | Compare |
| TNGX Tango Therapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IOVA Iovance Biotherapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | +80.07% (above 0%: growing) | n/m | +89.72% (above 0%: growing) | 0.00% | (19.73%) | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.4B | 119× | 81.2× | +45.05% (above 0%: growing) | +16.67% (above 0%: growing) | +1,171.89% (above 0%: growing) | 91.34% | 6.56% | Compare |
| Median of peers | $3.6B | — | — | +45.05% | — | −1.22% | 77.94% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 7.36m | 7.87m | 285.64 |
| 2024 | 7.60m | 35.60m | 307.34 |
| 2023 | 3.98m | 9.61m | 127.81 |
Ownership
Directors and executive officers, together
21.30%
Peter Thompson, M.D.
14.50%
OrbiMed Advisors LLC
14.40%
RA Capital Management, L.P.
9.70%
Baker Bros. Advisors LP
6.80%
Paradigm BioCapital Advisors LP
6.10%
BlackRock Inc.
5.40%
Novo Holdings A/S
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement